-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chronic myeloid leukemia (CML) is a hematopoietic stem cell (SC) tumor diagnosed by the expression of the t(9;22)(BCR-ABL1) fusion gene
.
A research team used flow cytometry to detect CD26+ CML leukemia stem cells (LSCs) to determine their value as an independent diagnostic investigation for CML and to detect residual disease in CML patients on treatment
.
Chronic myeloid leukemia (CML) is a hematopoietic stem cell (SC) tumor diagnosed by the expression of the t(9;22)(BCR-ABL1) fusion gene
Table 1: Antibody Panel
Table 1: Antibody PanelPeripheral blood (PB) and/or bone marrow (BM) samples were included for flow cytometry analysis in patients with clinically suspected CML/CML at follow-up
.
Peripheral blood (PB) and/or bone marrow (BM) samples were included for flow cytometry analysis in patients with clinically suspected CML/CML at follow-up
Figure 1: Flow cytometry density contour plot showing the sequential gating strategy employed to identify CD26+ chronic myeloid leukemia (CML) leukemia stem cells (LSCs)
.
Figure 1: Flow cytometry density contour plot showing the sequential gating strategy employed to identify CD26+ chronic myeloid leukemia (CML) leukemia stem cells (LSCs)
.
Figure 2: Workflow and Notable Findings
Figure 2: Workflow and Notable FindingsA total of 104 samples (63 PB and 41 BM) from 64 patients [suspected CML (n = 30), CML at follow-up (n = 15), and non-CML (n = 19)] were examined
.
A total of 104 samples (63 PB and 41 BM) from 64 patients [suspected CML (n = 30), CML at follow-up (n = 15), and non-CML (n = 19)] were examined
Table 2: Baseline data and follow-up characteristics of the neonatal CML group and CML patients
Table 2: Baseline data and follow-up characteristics of the neonatal CML group and CML patientsAbbreviations: ALL, acute lymphoblastic leukemia/lymphoma; AML, acute myeloid leukemia; AP, accelerated phase; BC, blast crisis phase; CHR, complete hematologic response; CML, chronic myeloid leukemia; CP, chronic phase; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; N, number
.
Abbreviations: ALL, acute lymphoblastic leukemia/lymphoma; AML, acute myeloid leukemia; AP, accelerated phase; BC, blast crisis phase; CHR, complete hematologic response; CML, chronic myeloid leukemia; CP, chronic phase; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; N, number
Overall, flow cytometric identification of CD26+ LSCs in peripheral blood can be an inexpensive, rapid, reliable and potential diagnostic tool for CML compared to existing detection methods .
Original source:
Original source:Sharma P, Sachdeva MUS, Naseem S, Sreedharanunni S, Das R, Malhotra P, Varma N.
Identification of peripheral blood CD26+ leukemic stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia.
Int J Lab Hematol.
2022 Feb 9 .
doi: 10.
1111/ijlh.
13807.
Epub ahead of print.
PMID: 35142061.
Identification of peripheral blood CD26+ leukemic stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia.
Int J Lab Hematol.
2022 Feb 9 .
doi: 10.
1111/ijlh.
13807.
Epub ahead of print.
PMID: 35142061.
Sharma P, Sachdeva MUS, Naseem S, Sreedharanunni S, Das R, Malhotra P, Varma N.
Identification of peripheral blood CD26+ leukemic stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia.
Int J Lab Hematol.
2022 Feb 9.
doi: 10.
1111/ijlh.
13807.
Epub ahead of print.
PMID: 35142061.
Leave a comment here
